GlassScriptPhysician profile
Vijay Patel
NPI 1538250980
$2,753.13
in general payments reported to CMS, 2019-2025
26 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $536 · 2021: $533 · 2022: $164 · 2023: $377 · 2024: $184 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613 · Travel and Lodging: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.86 |
| Travel and Lodging | $418.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $418.83 | 2025 | Scopis Ent |
| Janssen Pharmaceuticals, INC | $405.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.80 | 2020-2024 | Jardiance |
| Philips North America LLC | $185.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $176.08 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $164.90 | 2020-2023 | Mounjaro |
| Pfizer INC. | $114.37 | 2020-2024 | |
| Amgen INC. | $104.81 | 2023 | Repatha, Evenity, Prolia |
| Amarin Pharma, INC. | $88.45 | 2019-2021 | |
| Allergan, INC. | $81.95 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $79.67 | 2019-2023 | Farxiga, Breztri |
| Mannkind Corporation | $78.50 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $75.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.46 | 2019 | |
| Abiomed | $52.26 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $49.15 | 2021-2022 | |
| Novo Nordisk INC | $39.34 | 2023 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $35.03 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.03 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.74 | 2023 | Seglentis |
| Dexcom, INC. | $22.24 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.08 | 2019 | |
| Astellas Pharma US INC | $19.66 | 2020 | |
| Boston Scientific Corporation | $15.54 | 2023 | Watchman Access System |
| Exact Sciences Corporation | $13.75 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.